Oppenheimer downgraded Arvinas (ARVN) to Perform from Outperform and removed the firm’s price target on the shares after the company announced ...

Oppenheimer downgraded Arvinas (ARVN ... of investors polled in a recent survey said they wanted to see the trial hit on the Intention-to-Treat endpoint and argues that without an ITT win it ...

added ~9% in the premarket on Friday after Oppenheimer upgraded the biopharma to Outperform from Perform, citing a favorable valuation setup ahead of a mid-stage trial readout for its eczema ...

Oppenheimer reiterates a Perform rating on Cartesian Therapeutics (RNAC) without a price target following the company’s Q4 report.The company’s Phase 3 trial in myasthenia gravis remains on ...

On Tuesday, Oppenheimer reaffirmed its positive stance on Kala Pharmaceuticals (NASDAQ ... The company is making progress with its Phase 2b trial for persistent corneal epithelial defect (PCED), ...

On Tuesday, Oppenheimer reaffirmed its positive stance ... The company is making progress with its Phase 2b trial for persistent corneal epithelial defect (PCED), having randomized 87 patients ...